[HTML][HTML] WHO's essential medicines and AWaRe: recommendations on first-and second-choice antibiotics for empiric treatment of clinical infections

L Moja, V Zanichelli, D Mertz, S Gandra… - Clinical Microbiology …, 2024 - Elsevier
Abstract The WHO Model List of Essential Medicines (EML) prioritizes medicines that have
significant global public health value. The EML can also deliver important messages on …

[HTML][HTML] Guidelines for diagnosis and management of community-and hospital-acquired pneumonia in adults: Joint ICS/NCCP (I) recommendations

D Gupta, R Agarwal, AN Aggarwal, N Singh… - Lung India, 2012 - journals.lww.com
3. Chest radiograph should be repeated if the patient is not improving and also for all those
patients who have persistence or worsening of symptoms/physical signs or those in whom …

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)

I Kuzman, A Bezlepko, I Kondova Topuzovska… - BMC pulmonary …, 2014 - Springer
Background Community acquired pneumonia (CAP) is a major cause of morbidity,
hospitalization, and mortality worldwide. Management of CAP for many patients requires …

Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis

YQ Zhang, SL Zou, H Zhao, MM Zhang… - The American Journal of …, 2018 - Elsevier
Background The goal of this study was to investigate whether ceftriaxone combination
therapy is associated with better clinical outcomes than respiratory fluoroquinolone …

Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials

X Yuan, BB Liang, R Wang, YN Liu, CG Sun… - Journal of …, 2012 - Taylor & Francis
Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality
throughout the world. To investigate whether moxifloxacin monotherapy is associated with …

Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections

J Fernandez, JJ Hilliard, BJ Morrow… - Antimicrobial agents …, 2011 - Am Soc Microbiol
The in vivo efficacy of JNJ-Q2, a new broad-spectrum fluoroquinolone (FQ), was evaluated
in a murine septicemia model with methicillin-susceptible Staphylococcus aureus (MSSA) …

[HTML][HTML] Improvement in clinical and economic outcomes with empiric antibiotic therapy covering atypical pathogens for community-acquired pneumonia patients: a …

X Ye, J Ma, B Hu, X Gao, L He, W Shen, L Weng… - International Journal of …, 2015 - Elsevier
Objective To determine the effectiveness of empiric antibiotic regimens covering atypical
pathogens with respect to detailed clinical and economic outcomes in community-acquired …

Antihypertensive effects and safety of eprosartan: a meta-analysis of randomized controlled trials

FY Xu, B Yang, D Shi, H Li, Z Zou, XY Shi - European journal of clinical …, 2012 - Springer
Purpose The benefits of reducing blood pressure (BP) have been well established, but
uncertainty remains about the comparative effects of different BP-lowering regimens. We …

What is new in antibiotic therapy in community-acquired pneumonia? An evidence-based approach focusing on combined therapy

S Gattarello - Current infectious disease reports, 2015 - Springer
Despite all published literature, controversies remain about the optimal antibiotic treatment
in community-acquired pneumonia. The most debated issue is whether it is necessary to …

[引用][C] 近5 年药物临床试验实施过程中存在问题的问卷调查

马春明, 赵亚利, 詹思延 - 药物流行病学杂志, 2012